PF-02341066, a new drug to treat advanced non-small cell lung cancer, from Pfizer will soon go for Phase 3 clinical studies.
PF-02341066 is an oral c-Met and ALK inhibitor.
PF-02341066’s Phase 3 clinical trial versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy, will be started soon Pfizer Oncology announced.
PF-02341066 is a selective, ATP-competitive small molecule dual inhibitor of mesenchymal epithelial transition growth factor (c-Met or hepatocyte growth factor) and ALK tyrosine kinases, which are implicated in the progression of several cancers, including NSCLC.
A subset of NSCLC patients have been identified whose tumors carry a unique mutation in which the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to ALK, also known as an EML4-ALK translocation.
This fusion/translocation of genes has been reported in 3-7 percent of all NSCLC patients, with the incidence increasing to 10-20 percent among NSCLC patients with adenocarcinoma histology and those who have a never-to-light smoking history, and represents one of the newest molecular targets in NSCLC.
“By focusing on the subset of patients whose lung cancers carry the EML4-ALK translocation, we will be in the best position to determine the clinical effects of PF-02341066, both good and bad, in comparison to standard chemotherapy,” stated Dr Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer’s Oncology Business Unit.
Lung cancer is the most common cancer worldwide, with NSCLC accounting for approximately 85 percent of lung cancer cases. Nearly 60 percent of NSCLC patients are diagnosed late with Stage IIIB/IV advanced disease. For Stage IIIB/IV NSCLC, the five-year survival rate is only 12 percent.
PF-02341066’s phase 3 randomized, open-label study will evaluate the anti-tumor activity and safety of the drug versus pemetrexed or docetaxel in patients with measurable NSCLC who have tested positive for the ALK fusion gene and who have progressed on a platinum-based chemotherapy is currently open and enrolling in the United States and will be enrolling globally by the end of 2009. The study is expected to enroll 318 patients.
The primary objective of the study is progression-free survival and secondary outcomes include assessment of overall survival, objective response rate, duration of response, disease control rate, and patient-reported outcomes.
Patients in the study will be randomized to receive PF-02341066 (250 mg orally BID) or pemetrexed (500 mg/m2 on Day 1 of each 21 day cycle) or docetaxel (75 mg/m2 on Day 1 of each 21 day cycle).
Earlier, results from an expansion cohort of a Phase 1 study in patients with NSCLC carrying the ALK fusion gene showed early clinical activity with PF-02341066.
In this study, patients carrying the EML4-ALK translocation were recruited into an expanded cohort at the recommended Phase 2 dose of 250 mg twice daily (BID). To date, 31 NSCLC ALK patients have been evaluated for response.
The overall response rate, to date, is 65 percent (20/31 patients [95 percent CI: 45 percent, 81 percent]) and disease control rate (DCR) at 8 weeks is 84 percent (26/31 patients [95 percent CI: 66 percent, 95 percent]). Median PFS has not yet been reached. The median duration of treatment is over 24.5 weeks.
In the Phase 1 study, the most common adverse events were mild or moderate, and included nausea, vomiting and diarrhea. Treatment-related severe toxicity (elevated liver transaminases) was infrequent and reversible.
This expansion cohort was part of a dose-escalation study which enrolled 38 advanced cancer patients in the escalation phase, and 57 patients in the expansion cohort, with various tumors, including NSCLC, colorectal, pancreatic, sarcoma and anaplastic large cell lymphoma tumors.